Marker Therapeutics Inc (MRKR)

[hanscott]

Excellent presentation. I think this approach using multiple overlaping epitopes (as it recruits even very rare Tcell clones), and the persistence of the subsequent memory Tcell clones (vs CAR-T's limited to the individually modified Tcell lifespan) gives this therapy an enormous advantage and easily offers patients the best hope of long lasting remission compared to CAR-T approaches.

I wonder what exactly he means at 10:26 "this program has flown under the radar at Baylor." I'm assuming he meant the program at Baylor has flown under the radar of the oncology community in general, which might explain why other companies did not go after them.